International Journal of STD & AIDS > Volume 19, Number 10 > Pp. 665-667

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zelin, J Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

An evaluation of the performance of OraQuick^® ADVANCE Rapid HIV-1/2 Test in a high-risk population attending genitourinary medicine clinics in East London, UK

J Zelin FRCOG ^* , N Garrett MRCP , J Saunders MRCP , F Warburton MSc , J Anderson PhD, FRCP , K Moir BA (Hons) ^*, M Symonds RMN PGDMS ^*, C Estcourt MD, FRCP ^* ** on behalf of the North East London Sexual Health Network Research Consortium

^* Barts Sexual Health Centre, Barts and The London NHS Trust, London EC1A 7BE; Department of Sexual Health, Homerton University Hospital NHS Foundation Trust, London E9 6SR; Greenway Centre, Newham University Hospital NHS Trust, London E13 8SL; Joint Research Office, Bart's and The London NHS Trust, Queen Mary's School of Medicine and Dentistry, London E1 2AN; ^** Centre For Infectious Disease, Institute For Cell And Molecular Science, Barts and the London School of Medicine and Dentistry, London E1 2AT, UK

Correspondence to: Dr Jill Zelin Email: Jill.Zelin{at}bartsandthelondon.nhs.uk

To date, no data have been published on the use of OraQuick^® ADVANCE Rapid HIV-1/2 Test (OraQuick) in the UK. We report preliminary findings of an ongoing evaluation of OraQuick in UK genitourinary (GU) medicine clinics. A total of 820 samples from patients in high-risk groups for HIV were tested with OraQuick and results were compared with standard HIV antibody testing. HIV prevalence (enzyme immunoassay [EIA]) was 5.73%, sensitivity of OraQuick was 93.64% (95% CI 82.46–98.66%), specificity 99.87% (99.28–100%), positive predictive value 97.78% (88.27–99.94%) and negative predictive value 99.61% (98.87–99.92%). This includes three false-negatives considered to be due to observer error and now rectified by further training. This has increased test sensitivity to 100%. Our observed test performance of OraQuick compares well with EIA and with other rapid tests. We believe that simple, non-invasive antibody detection tests such as OraQuick can increase HIV testing and diagnosis in UK GU medicine and community settings.

Key Words: point-of-care • oral fluid • HIV • rapid, tests

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?